This Article Full Text Full Text (PDF) Other Versions of this Article: CVI.00427-07v1 15/3/582    most recent Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Copyright Information Books from ASM Press MicrobeWorld Google Scholar Articles by Lin, L. Articles by Spellberg, B. PubMed PubMed Citation Articles by Lin, L. Articles by Spellberg, B.

Considerable Differences in Vaccine Immunogenicities and Efficacies Related to the Diluent Used for Aluminum Hydroxide Adjuvant

Division of Infectious Diseases, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, California,¹ the David Geffen School of Medicine at UCLA, Los Angeles, California²

Received 29 October 2007/ Returned for modification 1 January 2008/ Accepted 4 January 2008

We are developing an anticandidal vaccine using the recombinant N terminus of Als3p (rAls3p-N). We report that although more rAls3p-N was bound by aluminum hydroxide diluted in saline than by aluminum hydroxide diluted in phosphate-buffered saline (PBS), its immunogenicity and efficacy were superior in PBS. Thus, protein binding, by itself, may not predict the efficacy of some vaccines with aluminum adjuvants.

Published ahead of print on 9 January 2008.